Study summary

A PSMA radioligand added to hormone therapy delayed progression in newly treated disease

PSMAddition trial (Lu-PSMA-617 earlier) · 1,144 men, phase 3 (interim analysis) · Published August 2026, The Lancet

28%lower risk of progression or death

What was tested

Lutetium-177 PSMA-617 (Pluvicto), a radioactive drug that seeks out the PSMA protein on prostate cancer cells, added to hormone therapy (ADT plus an androgen receptor pathway inhibitor) for PSMA-positive metastatic hormone-sensitive prostate cancer.

What they found

What it means

Could move Lu-PSMA from late-stage treatment to the first year after diagnosis; survival results will decide.

Lancet, via PubMed ↗ Trial record NCT04720157 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.